Tendas A, et al. - Given that high-dose melphalan (HDMel) is the most common conditioning chemotherapy regimen for autologous stem cell transplantation (SCT) in patients affected by multiple myeloma (MM) and there is no existing consensus for the emetogenicity or prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in this regimen, researchers extracted data on the incidence and efficacy/safety of CINV prophylaxis among patients affected by MM undergoing autologous SCT with the HDMel regimen. Analyzing 11 studies involving multiple CINV prophylaxis regimens, they identified an aprepitant-based three-drug regimen (aprepitant + serotonin receptor antagonist (5HT3RA) + dexamethasone) as better regarding efficacy than a two-drug regimen (5HT3RA + dexamethasone) for CINV prevention without increasing the frequency in adverse events.